Cohance Lifesciences: USFDA inspection closes
Cohance Lifesciences Limited has received the Establishment Inspection Report (EIR) for its Shamshabad formulation facility. The USFDA classified the inspection as Voluntary Action Indicated (VAI), and the inspection process is now concluded. Why it matters: Regulatory observations at manufacturing facilities can affect a pharma company's ability to supply regulated markets. Closure of the inspection is an important development, but VAI is not the same as a No Action Indicated classification. What to watch: The focus now shifts to the company's corrective and preventive actions, compliance track record and any further regulatory communication. My view: A development worth monitoring, but investors should not interpret the inspection closure as a clean regulatory bill of health. The distinction between VAI and NAI matters.



















